Literature DB >> 23295921

Direct and indirect anti-inflammatory effects of tulathromycin in bovine macrophages: inhibition of CXCL-8 secretion, induction of apoptosis, and promotion of efferocytosis.

Carrie D Fischer1, Jennifer K Beatty, Stephanie C Duquette, Douglas W Morck, Merlyn J Lucas, André G Buret.   

Abstract

Recent evidence indicates that immunomodulation by antibiotics may enhance their clinical efficacy. Specifically, drug-induced leukocyte apoptosis and macrophage efferocytosis have been shown to promote the resolution of inflammation in a variety of disease settings. Tulathromycin is a new macrolide antibiotic for the treatment of bovine respiratory disease. The direct antimicrobial effects of the drug alone do not fully justify its superior clinical efficacy, and we hypothesize that tulathromycin may have immunomodulating properties. We recently reported that tulathromycin promotes apoptosis and inhibits proinflammatory NF-κB signaling in bovine neutrophils. In this study, we investigated the direct and indirect anti-inflammatory effects of tulathromycin in bovine macrophages. The findings indicate that bovine monocyte-derived macrophages and alveolar macrophages readily phagocytose tulathromycin-induced apoptotic neutrophils both in vitro and in the airways of Mannheimia haemolytica-infected calves. Moreover, tulathromycin promotes delayed, concentration-dependent apoptosis, but not necrosis, in bovine macrophages in vitro. Activation of caspase-3 and detection of mono- and oligonucleosomes in bovine monocyte-derived macrophages treated with tulathromycin was observed 12 h posttreatment; pretreatment with a pan-caspase inhibitor (ZVAD) blocked the proapoptotic effects of the drug. Lastly, tulathromycin inhibited the secretion of proinflammatory CXCL-8 in lipopolysaccharide (LPS)-stimulated bovine macrophages; this effect was independent of caspase activation or programmed cell death. Taken together, these immunomodulating effects observed in bovine macrophages help further elucidate the mechanisms through which tulathromycin confers anti-inflammatory and proresolution benefits. Furthermore, these findings offer novel insights on how antibiotics may offer anti-inflammatory benefits by modulating macrophage-mediated events that play a key role in inflammation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23295921      PMCID: PMC3591872          DOI: 10.1128/AAC.01598-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  54 in total

1.  Pasteurella haemolytica leukotoxin and endotoxin induced cytokine gene expression in bovine alveolar macrophages requires NF-kappaB activation and calcium elevation.

Authors:  S L Hsuan; M S Kannan; S Jeyaseelan; Y S Prakash; C Malazdrewich; M S Abrahamsen; G C Sieck; S K Maheswaran
Journal:  Microb Pathog       Date:  1999-05       Impact factor: 3.738

2.  Immunosuppressive effects of apoptotic cells.

Authors:  R E Voll; M Herrmann; E A Roth; C Stach; J R Kalden; I Girkontaite
Journal:  Nature       Date:  1997-11-27       Impact factor: 49.962

3.  Complement fragment C5a and inflammatory cytokines in neutrophil recruitment during intramammary infection with Escherichia coli.

Authors:  D E Shuster; M E Kehrli; P Rainard; M Paape
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

4.  Infection by Mycobacterium tuberculosis promotes human alveolar macrophage apoptosis.

Authors:  J Keane; M K Balcewicz-Sablinska; H G Remold; G L Chupp; B B Meek; M J Fenton; H Kornfeld
Journal:  Infect Immun       Date:  1997-01       Impact factor: 3.441

5.  In vivo fate of the inflammatory macrophage during the resolution of inflammation: inflammatory macrophages do not die locally, but emigrate to the draining lymph nodes.

Authors:  G J Bellingan; H Caldwell; S E Howie; I Dransfield; C Haslett
Journal:  J Immunol       Date:  1996-09-15       Impact factor: 5.422

6.  Pasteurella haemolytica leukotoxin-induced synthesis of eicosanoids by bovine neutrophils in vitro.

Authors:  K D Clinkenbeard; C R Clarke; C M Hague; P Clinkenbeard; S Srikumaran; R J Morton
Journal:  J Leukoc Biol       Date:  1994-11       Impact factor: 4.962

7.  Pathogenic Mycobacterium tuberculosis evades apoptosis of host macrophages by release of TNF-R2, resulting in inactivation of TNF-alpha.

Authors:  M K Balcewicz-Sablinska; J Keane; H Kornfeld; H G Remold
Journal:  J Immunol       Date:  1998-09-01       Impact factor: 5.422

8.  Anti-inflammatory benefits of tilmicosin in calves with Pasteurella haemolytica-infected lungs.

Authors:  A C Chin; D W Morck; J K Merrill; H Ceri; M E Olson; R R Read; P Dick; A G Buret
Journal:  Am J Vet Res       Date:  1998-06       Impact factor: 1.156

9.  Phosphorylation of IkappaB-alpha inhibits its cleavage by caspase CPP32 in vitro.

Authors:  M Barkett; D Xue; H R Horvitz; T D Gilmore
Journal:  J Biol Chem       Date:  1997-11-21       Impact factor: 5.157

10.  Macrophage recruitment during limb development and wound healing in the embryonic and foetal mouse.

Authors:  J Hopkinson-Woolley; D Hughes; S Gordon; P Martin
Journal:  J Cell Sci       Date:  1994-05       Impact factor: 5.285

View more
  7 in total

1.  Tamoxifen induces apoptotic neutrophil efferocytosis in horses.

Authors:  C Olave; N Morales; B Uberti; C Henriquez; J Sarmiento; A Ortloff; H Folch; G Moran
Journal:  Vet Res Commun       Date:  2018-01-02       Impact factor: 2.459

2.  Lung Ultrasonography and Clinical Follow-Up Evaluations in Fattening Bulls Affected by Bovine Respiratory Disease (BRD) during the Restocking Period and after Tulathromycin and Ketoprofen Treatment.

Authors:  Enrico Fiore; Anastasia Lisuzzo; Andrea Beltrame; Barbara Contiero; Matteo Gianesella; Eliana Schiavon; Rossella Tessari; Massimo Morgante; Elisa Mazzotta
Journal:  Animals (Basel)       Date:  2022-04-12       Impact factor: 3.231

3.  Tulathromycin exerts proresolving effects in bovine neutrophils by inhibiting phospholipases and altering leukotriene B4, prostaglandin E2, and lipoxin A4 production.

Authors:  Carrie D Fischer; Stephanie C Duquette; Bernard S Renaux; Troy D Feener; Douglas W Morck; Morley D Hollenberg; Merlyn J Lucas; Andre G Buret
Journal:  Antimicrob Agents Chemother       Date:  2014-05-12       Impact factor: 5.191

4.  Efficacy of Tulathromycin for the Treatment of Foals with Mild to Moderate Bronchopneumonia.

Authors:  D Rutenberg; M Venner; S Giguère
Journal:  J Vet Intern Med       Date:  2017-04-19       Impact factor: 3.333

5.  Immuno-modulating properties of Tulathromycin in porcine monocyte-derived macrophages infected with porcine reproductive and respiratory syndrome virus.

Authors:  D Desmonts de Lamache; R Moges; A Siddiq; T Allain; T D Feener; G P Muench; N McKenna; R M Yates; A G Buret
Journal:  PLoS One       Date:  2019-08-23       Impact factor: 3.240

6.  Limitations of bacterial culture, viral PCR, and tulathromycin susceptibility from upper respiratory tract samples in predicting clinical outcome of tulathromycin control or treatment of bovine respiratory disease in high-risk feeder heifers.

Authors:  Jeffrey J Sarchet; John P Pollreisz; David T Bechtol; Mitchell R Blanding; Roger L Saltman; Patrick C Taube
Journal:  PLoS One       Date:  2022-02-10       Impact factor: 3.240

7.  Anti-Inflammatory Benefits of Antibiotics: Tylvalosin Induces Apoptosis of Porcine Neutrophils and Macrophages, Promotes Efferocytosis, and Inhibits Pro-Inflammatory CXCL-8, IL1α, and LTB4 Production, While Inducing the Release of Pro-Resolving Lipoxin A4 and Resolvin D1.

Authors:  Ruth Moges; Dimitri Desmonts De Lamache; Saman Sajedy; Bernard S Renaux; Morley D Hollenberg; Gregory Muench; Elizabeth M Abbott; Andre G Buret
Journal:  Front Vet Sci       Date:  2018-04-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.